NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

iclight,

Wrong! Truly unbiased opinions are always welcome but when someone dismisses things pretty much out of hand or comments without detailing the entire picture because of likely conflicts of interest then that’s a problem. Many folks here have more “skin in the game” through personal connections to GBM patients and have been looking for a cure than those who constantly bash so we are likely to call out those who do not present the entirety of the picture. The interview at Brown University with the folks looking at the data clearly gave pluses and minuses in their comments about the data. They were objective and still consider DCVax-L a breakthrough because the data is still very compelling in spite of the known limitations created by trial design with crossover which ended up being best for the patients even if not best for the interpretation of trial results in absolutist terms. The problem with absolutists is they give no reasonable consideration for what might be best for patients but believe it or not, most times regulators do; ). Best wishes.